Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: Clinical and research challenges

Diabetes Care

Volumn 27, Issue 11, 2004, Pages 2752-2754

  Hennekens, Charles H ^a,b,c   Knatterud, Genell L ^d   Pfeffer, Marc A ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Agatston Research Institute   (United States)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

^d MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETES MELLITUS; DRUG POTENTIATION; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROPHYLAXIS; RETINOPATHY; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION INHIBITION; VITREOUS HEMORRHAGE;

EID: 7444255988     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.11.2752     Document Type: Note

References (23)

1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel or ATP III): Executive summary of the third report of the National Cholesterol Program (NCEP III). JAMA 285:2486-2497, 2001
2. Eidelman RS, Lamas GA, Hennekens CH: The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary hear disease. Arch Intern Med 162:2033-2038, 2002
3. Hennekens CH: Increasing global burden of cardiovascular disease: current knowledge and future directions for research on risk factors: special report: the 1997 American Heart Association's Lewis Atterbury Conner Lecture. Circulation 97:1095-1102, 1998
4. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krowlewski As, Rosner B, Arky RA, Speizer FE, Hennekens CH: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151:1141-1147, 1991
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
6. Hennekens CH, Burring JE, Sandercock P, Collins R, Peto R: Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80:749-756, 1989
7. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324:71-86, 2002
8. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE: Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 85:265-271, 2001
9. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch Int Med 163:2006-2010, 2003
10. United States Preventive Services Task Force: Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 136z: 157-160, 2002
11. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA: AHA guidelines for primary prevention of cardiovascular diseases and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106:388-391, 2002
12. American Diabetes Association: Aspirin therapy in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S72-S73, 2004
13. Early Treatment Diabetic Retinopathy Study Research Group: Effects of aspirin treatment on diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 8. Ophthalmology 98:757-765, 1991
14. Early Treatment Diabetic Retinopathy Study Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 268:1292-1300, 1992
15. Chew EY, Klein ML, Murphy RP, Remaley NA, Ferris FL, for the Early Treatment Diabetic Retinopathy Study Research Group: Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study Report No. 29. Arch Ophthalmol 113:52-55, 1995
16. UK-TIA Study Group: United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: interim results. Br Med J 296:316-320, 1988
17. Cook NR, Chae CU, Mueller FB, Landis S, Saks AM, Hennekens CH: Mismedication and under-utilization of aspirin in the prevention and treatment of cardiovascular disease [Article online]. MedGenMed (serial online), 1999. Available from http/www.medscape.comviewarticle/408025. Accessed 20 December 2002
18. Reilly IA, FitzGerald GA: Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69:180-186, 1987
19. Fitzgerald, GA: Parsing an enigma: the pharmacodynamics of aspirin resistance (Editorial). Lancet 361:542, 2003
20. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359:118-124, 2002
21. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998 [erratum in Lancet 354:602, 1999]
22. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998 [erratum in Lancet 354:602, 1999]
23. Holman RR, Cull CA, Turner RC: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83-88, 1995